{"product_id":"ucsf-41st-annual-advances-in-heart-disease-2024","title":"UCSF 41st Annual Advances in Heart Disease 2024","description":"\u003ch3 class=\"product_title entry-title\"\u003eUCSF 41st Annual Advances in Heart Disease 2024\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eInclude: 5 videos, size: 7.91 GB\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e Target Audience: cardiovascular specialists, practicing cardiologists, internists, family physicians, cardiovascular and critical care physician assistants\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e Information:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cp\u003eOur 41st annual course will again strive to present topics that highlight new evidence-based medicine findings reported within the last one to two years that impact clinical practice. These will range across a variety of weight loss drugs and heart health, heart failure, contemporary management of arrhythmias, critical care cardiology, mechanical circulatory support, erectile dysfunction and heart health, and pulmonary hypertension.\u003c\/p\u003e\n\u003cp\u003eOur faculty will include a distinguished group of visiting academicians from North America together with outstanding teachers and clinicians from the University of California, San Francisco.\u003c\/p\u003e\n\u003cp\u003eAll sessions will be recorded and made available to participants for online viewing 30 days post course.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eTARGET AUDIENCE\u003c\/strong\u003e\u003cbr\u003eThis course is intended for cardiovascular specialists, practicing cardiologists, internists, family physicians, cardiovascular and critical care nurses, and physician assistants.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003e\u003cstrong\u003eObjectives\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProviding the Best Management of Coronary Heart Disease, Hypertension, Lipid Disorders, Diabetes, Systolic and Diastolic Heart Failure, Atrial Fibrillation and Flutter, STEMI and Non-STEMI, Thromboembolic Disease;\u003c\/li\u003e\n\u003cli\u003eRefining Considerations for Atrial Fibrillation, Atrial Flutter, and Ventricular Tachycardia Ablation;\u003c\/li\u003e\n\u003cli\u003eApplying the Best Considerations of Percutaneous Interventions for Coronary Heart Disease;\u003c\/li\u003e\n\u003cli\u003eImproving the Use of Anti-Platelet and Anti-Coagulation Therapy for Cardiovascular Diseases;\u003c\/li\u003e\n\u003cli\u003eRecognizing Risk Stratification of Cardiovascular Disease;\u003c\/li\u003e\n\u003cli\u003eOptimizing the Management of Peripheral Artery Disease;\u003c\/li\u003e\n\u003cli\u003eRecognizing that Pathophysiology of Diseases and Treatment Options Differ among Racial and Ethnic Groups;\u003c\/li\u003e\n\u003cli\u003eOptimizing the Management of COVID-19 and its Cardiovascular Complications.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e Topics:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDecember 6 AM Session.mp4\u003c\/li\u003e\n\u003cli\u003eDecember 6 PM Session.mp4\u003c\/li\u003e\n\u003cli\u003eDecember 7 AM Session.mp4\u003c\/li\u003e\n\u003cli\u003eDecember 7 PM Session.mp4\u003c\/li\u003e\n\u003cli\u003eDecember 8 AM Session.mp4\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e* Detail:\u003c\/p\u003e\n\u003ctable width=\"1864\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"3\"\u003e\u003cstrong\u003eFriday, December 6, 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"80\"\u003e7:00 AM\u003c\/td\u003e\n\u003ctd width=\"566\"\u003e\u003cem\u003eRegistration and Continental Breakfast\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd width=\"296\"\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e8:00\u003c\/td\u003e\n\u003ctd width=\"566\"\u003eWelcome and Symposium Overview\u003c\/td\u003e\n\u003ctd\u003ePeter Ganz, MD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\"\u003e\u003cstrong\u003eSession: Frontiers in Interventional Cardiology\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eChair: Lucas Zier, MD, MS \u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e8:05\u003c\/td\u003e\n\u003ctd width=\"566\"\u003eMyocardial Infarction Without Obstructive Coronary Disease. What to Do?\u003c\/td\u003e\n\u003ctd\u003eKrishan Soni, MD, MBA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e8:45\u003c\/td\u003e\n\u003ctd width=\"566\"\u003eComplete Revascularization vs Culprit Only Revascularization: Understanding Each Strategy and When to Perform Each Approach\u003c\/td\u003e\n\u003ctd\u003eAda Ip, MD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e9:25\u003c\/td\u003e\n\u003ctd width=\"566\"\u003eOrbita vs Orbita 2: Update on PCI for Stable CAD.\u003c\/td\u003e\n\u003ctd\u003eLucas Zier, MD, MS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e10:05\u003c\/td\u003e\n\u003ctd width=\"566\"\u003e\u003cem\u003eCoffee Break\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e10:20\u003c\/td\u003e\n\u003ctd width=\"566\"\u003e2024 Updates on the Management of Valve Disease\u003c\/td\u003e\n\u003ctd\u003eSammy Elmariah , MD, MPH\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e11:00\u003c\/td\u003e\n\u003ctd width=\"566\"\u003eSurgical Management of Type A Aortic Dissection\u003c\/td\u003e\n\u003ctd\u003eRamin Beygui, MD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e11:40\u003c\/td\u003e\n\u003ctd width=\"566\"\u003eCirculatory Support in Cardiogenic Shock: New Data and a New Era?\u003c\/td\u003e\n\u003ctd\u003eConnor O’Brien, MD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e12:20 PM\u003c\/td\u003e\n\u003ctd width=\"566\"\u003e\u003cem\u003eLunch (on Your Own)\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\"\u003e\u003cstrong\u003eSession: Managing Heart Failure\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eChair: Jonathan Davis, MD, MPH\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1:40 PM\u003c\/td\u003e\n\u003ctd width=\"566\"\u003eNew Drugs and Devices Coming Down Pipeline for Heart Failure\u003c\/td\u003e\n\u003ctd\u003eLiviu Klein, MD, MS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2:15\u003c\/td\u003e\n\u003ctd width=\"566\"\u003eGenetic Testing for Heart Failure, Who Should Be Tested and What are We Looking For?\u003c\/td\u003e\n\u003ctd\u003eJulianne Wojciak, LGCG, MS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2:50\u003c\/td\u003e\n\u003ctd width=\"566\"\u003eHFrEF Management\u003c\/td\u003e\n\u003ctd\u003eJonathan Davis, MD, MPH\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3:25\u003c\/td\u003e\n\u003ctd width=\"566\"\u003e\u003cem\u003eCoffee Break\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3:40\u003c\/td\u003e\n\u003ctd width=\"566\"\u003eHFpEF Management\u003c\/td\u003e\n\u003ctd\u003eJacqueline DesJardin, MD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e4:15\u003c\/td\u003e\n\u003ctd width=\"566\"\u003eApproach to and Management of Hypertrophic Cardiomyopathy\u003c\/td\u003e\n\u003ctd\u003eTheodore Abraham, MD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e4:50\u003c\/td\u003e\n\u003ctd width=\"566\"\u003eApproach to and Management of Cardiac Amyloid\u003c\/td\u003e\n\u003ctd\u003eMandar Aras, MD, PhD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e5:25 PM\u003c\/td\u003e\n\u003ctd width=\"566\"\u003e\u003cem\u003eAdjourn\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd width=\"566\"\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"3\"\u003e\u003cstrong\u003eSaturday, December 7, 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e7:30 AM\u003c\/td\u003e\n\u003ctd width=\"566\"\u003e\u003cem\u003eContinental Breakfast\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e8:00\u003c\/td\u003e\n\u003ctd width=\"566\"\u003eAnnouncements\u003c\/td\u003e\n\u003ctd\u003ePeter Ganz, MD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\"\u003e\u003cstrong\u003eSession: Advances and Controversies in Electrophysiology\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eChair: Nora Goldschlager, MD\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e8:05\u003c\/td\u003e\n\u003ctd width=\"566\"\u003eUse and Misuse of Antiarrhythmic Drugs in 2025\u003c\/td\u003e\n\u003ctd\u003eGregory Marcus, MD, MAS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e8:45\u003c\/td\u003e\n\u003ctd width=\"566\"\u003eExtravascular Pacemakers and ICDs: Where Have All the Leads Gone?\u003c\/td\u003e\n\u003ctd\u003eAdam Oesterle, MD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e9:25\u003c\/td\u003e\n\u003ctd width=\"566\"\u003eConduction System Pacing: Benefits, Outcomes and Risks\u003c\/td\u003e\n\u003ctd\u003eJoshua Moss, MD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e10:05\u003c\/td\u003e\n\u003ctd width=\"566\"\u003e\u003cem\u003eCoffee Break\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e10:20\u003c\/td\u003e\n\u003ctd width=\"566\"\u003eArrhythmogenic  Cardiomyopathy\u003c\/td\u003e\n\u003ctd\u003eMelvin Scheinman, MD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e11:00\u003c\/td\u003e\n\u003ctd width=\"566\"\u003eWhat to Do with Incidentally Detected Atrial Fibrillation\u003c\/td\u003e\n\u003ctd\u003eCara Pellegrini, MD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e11:40\u003c\/td\u003e\n\u003ctd width=\"566\"\u003ePVCs and non-Sustained VT. When to Worry.\u003c\/td\u003e\n\u003ctd\u003eEdward Gerstenfeld, MD, MS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e12:20\u003c\/td\u003e\n\u003ctd width=\"566\"\u003e\u003cem\u003eLunch (on your own)\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1:40 PM\u003c\/td\u003e\n\u003ctd width=\"566\"\u003eAchieving a Successful Ablation. Achieving a Successful Ablation. Patient Selection and Outcomes.\u003c\/td\u003e\n\u003ctd\u003eThomas Dewland, MD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\"\u003e\u003cstrong\u003eSession: Cardiovascular Risk Reduction and Prevention\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eChair: Peter Ganz, MD\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2:20\u003c\/td\u003e\n\u003ctd width=\"566\"\u003eElliot Rapaport Keynote Lecture: How Failed Diabetes Drugs Led to a Revolution in Diabetes and Heart Failure Care. Convincing the FDA to Mandate Cardiovascular Outcome Trials for Diabetes Drug Approval\u003c\/td\u003e\n\u003ctd\u003eSteven Nissen, MD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3:05\u003c\/td\u003e\n\u003ctd width=\"566\"\u003eNew Prediction Tools from the AHA for Risk Assessment of Cardiovascular Disease\u003c\/td\u003e\n\u003ctd\u003ePeter Ganz, MD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3:45\u003c\/td\u003e\n\u003ctd width=\"566\"\u003e\u003cem\u003eCoffee Break\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e4:00\u003c\/td\u003e\n\u003ctd width=\"566\"\u003eCardiovascular Disease in Type 1 Diabetes\u003c\/td\u003e\n\u003ctd\u003eRobert Eckel, MD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e4:40\u003c\/td\u003e\n\u003ctd width=\"566\"\u003ePulmonary Hypertension, Contemporary Management and When to Refer\u003c\/td\u003e\n\u003ctd\u003eMarc Simon, MD, MS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e5:20 PM\u003c\/td\u003e\n\u003ctd width=\"566\"\u003e\u003cem\u003eAdjourn\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd width=\"566\"\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"3\"\u003e\u003cstrong\u003eSunday, December 8, 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e7:30 AM\u003c\/td\u003e\n\u003ctd width=\"566\"\u003e\u003cem\u003eContinental Breakfast\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e8:00\u003c\/td\u003e\n\u003ctd width=\"566\"\u003eAnnouncements\u003c\/td\u003e\n\u003ctd\u003ePeter Ganz, MD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\"\u003e\u003cstrong\u003eSession: Understanding and Managing Cardiovascular Risk\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eChair: Peter Ganz, MD\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e8:05\u003c\/td\u003e\n\u003ctd width=\"566\"\u003eSex diversity in heart-liver-metabolic axis risks and outcomes\u003c\/td\u003e\n\u003ctd\u003eSusan Cheng, MD, MMSc, MPH\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e8:45\u003c\/td\u003e\n\u003ctd width=\"566\"\u003ePDE-5 inhibitors for Erectile Dysfunction: Do They Have Cardiovascular Protective Properties\u003c\/td\u003e\n\u003ctd\u003eRobert Kloner, MD, PhD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e9:25\u003c\/td\u003e\n\u003ctd width=\"566\"\u003eThe Interplay of Cardiovascular and Kidney Disease\u003c\/td\u003e\n\u003ctd\u003eJulio Lamprea Montealegre, MD, PhD, MPH\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e10:05\u003c\/td\u003e\n\u003ctd width=\"566\"\u003eInsights from Basic Science to Advance Understanding of Heart Failure\u003c\/td\u003e\n\u003ctd\u003eArun Padmanabhan, MD, PhD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e10:25\u003c\/td\u003e\n\u003ctd width=\"566\"\u003eWeight Loss Drugs and Heart Health\u003c\/td\u003e\n\u003ctd\u003eMartha Gulati, MD, MS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e11:05\u003c\/td\u003e\n\u003ctd width=\"566\"\u003eManagement of Stroke – Updates\u003c\/td\u003e\n\u003ctd\u003eLauren Patrick, MD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e11:45\u003c\/td\u003e\n\u003ctd width=\"566\"\u003e\u003cem\u003eAdjourn\u003c\/em\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":" Ambossle","offers":[{"title":"Default Title","offer_id":46595641049313,"sku":"","price":80.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0750\/1925\/6033\/files\/UCSF-41st-Annual-Advances-in-Heart-Disease-2024-768x511.jpg?v=1751198923","url":"https:\/\/ambosslee.com\/products\/ucsf-41st-annual-advances-in-heart-disease-2024","provider":" Ambosslee","version":"1.0","type":"link"}